Macular Degeneration Treatment Market to Reach $33.7 Billion by 2035

Macular degeneration treatment market was valued at $18.8 billion in 2025 and is projected to reach $33.7 billion by 2035, growing at a CAGR of 6.0% during the forecast period (2026–2035). The increasing global burden of age-related vision impairment, particularly among the aging population, is significantly driving demand for effective macular degeneration treatments. According to data from the National Institutes of Health (NIH), approximately 2.2 billion people globally suffer from vision impairment or blindness, with age-related macular degeneration (AMD) being a leading cause among individuals aged 60 years and above. This rising prevalence is accelerating the adoption of advanced therapeutic interventions, including anti-VEGF therapies and emerging biologics, thereby strengthening market growth.

Browse the full report description of “Macular Degeneration Treatment Market Size, Share & Trends Analysis Report, By Type (Dry Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration), By Treatment Type (Anti-VEGF Therapy, Photodynamic Therapy, Laser Therapy, Nutritional Supplements, Emerging Therapies), By Drug Class (VEGF Inhibitors, Complement Inhibitors, Corticosteroids, Combination Therapies), By Route of Administration (Intravitreal, Intravenous), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/macular-degeneration-treatment-market

Dry age-related macular degeneration (Dry AMD) accounts for a significant patient pool, while wet AMD continues to dominate treatment demand due to the availability of targeted therapies. Among treatment types, anti-VEGF therapy remains the standard of care, supported by continuous innovations in drug delivery and long-acting formulations. The market is also witnessing growing interest in gene therapy and stem cell-based approaches, reflecting the shift toward disease-modifying and regenerative treatment strategies.

Rising Aging Population and Vision Impairment Burden

Globally, the aging population is expanding at an unprecedented rate, directly influencing the prevalence of macular degeneration. According to the United Nations Department of Economic and Social Affairs, the global population aged 65 years and above reached approximately 771 million in 2022 and is projected to surpass 1 billion by 2030. This demographic shift significantly increases the risk pool for age-related eye disorders, including AMD.

In the United States, data from the Centers for Disease Control and Prevention (CDC) indicates that nearly 20 million adults are affected by age-related macular degeneration, with prevalence expected to rise in the coming decade. This growing patient population is intensifying the demand for early diagnosis and effective treatment options, encouraging healthcare systems and pharmaceutical companies to expand access to innovative therapies.

Governments and healthcare organizations are also prioritizing vision care through national health initiatives and screening programs. For instance, between 2023 and 2025, several developed economies have strengthened reimbursement frameworks for anti-VEGF injections and advanced retinal therapies, improving patient accessibility and treatment adherence. These initiatives are playing a crucial role in accelerating market adoption and ensuring sustained demand across developed and emerging regions.

Innovation Leaders Transforming the Macular Degeneration Treatment Market

The key players in the macular degeneration treatment market include Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche (Genentech), Bayer AG, Novartis AG, and Apellis Pharmaceuticals, among others. These companies are actively engaged in advancing treatment efficacy through biologics, complement inhibitors, and next-generation therapies aimed at improving long-term visual outcomes.

• In February 2023,
• In March 2022, Oxurion NV

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  o By Type
  o By Treatment Type
  o By Drug Class

o Competitive Landscape – Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche (Genentech), Bayer AG, Novartis AG, Apellis Pharmaceuticals, among others

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Macular Degeneration Treatment Market Segment

By Type

• Dry Age-Related Macular Degeneration (Dry AMD)
• Wet Age-Related Macular Degeneration (Wet AMD)

By Treatment Type

• Anti-VEGF Therapy
• Photodynamic Therapy (PDT)
• Laser Therapy
• Nutritional Supplements
• Emerging Therapies

By Drug Class

• VEGF Inhibitors
• Complement Inhibitors
• Corticosteroids
• Combination Therapies

By Route of Administration

• Intravitreal
• Intravenous

Global Macular Degeneration Treatment Market Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/macular-degeneration-treatment-market